Evidence map›Paper›PMID 20547842›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2010

Interference with Sin3 function induces epigenetic reprogramming and differentiation in breast cancer cells.

Eduardo F Farias, Kevin Petrie, Boris Leibovitch, Janice Murtagh, Manuel Boix Chornet, Tino Schenk, Arthur Zelent, Samuel Waxman

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 67 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. SIN3B Loss Heats up Cold Tumor Microenvironment to Boost Immunotherapy in Pancreatic Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs).International journal of molecular sciences · 2020
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Eduardo F FariasDepartment of Medicine, Division of Hematology and Oncology, Tisch Cancer Center, Mount Sinai School of Medicine, New York, NY 10029, USA.
Kevin Petrie
Boris Leibovitch
Janice Murtagh
Manuel Boix Chornet
Tino Schenk
Arthur Zelent
Samuel Waxman
Icahn School of Medicine at Mount Sinai · USInstitute of Cancer Research · GB

Funding

Targeted epigenetic therapy of triple-negative breast cancerR01CA158121 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WAXMAN, SAMUEL · 2011 to 2015
$1.6M
Advanced Microscopy Shared Resource FacilityR24CA095823 · NCI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI FRIEDRICH, VICTOR LOUIS · 2002 to 2006
$1.3M
CONFOCAL MICROSCOPE FACILITYS10RR009145 · NCRR · MOUNT SINAI SCHOOL OF MEDICINE OF CUNY · PI MASUR, SANDRA K · 1994 to 1994
–
NCI NIH HHS 5R24-CA095823-04NCI NIH HHS R01 CA158121NCI NIH HHS R24 CA095823NCRR NIH HHS 1S10-RR0-9145-01
6 · The paper itself

Abstract

Sin3A/B is a master transcriptional scaffold and corepressor that plays an essential role in the regulation of gene transcription and maintenance of chromatin structure, and its inappropriate recruitment has been associated with aberrant gene silencing in cancer. Sin3A/B are highly related, large, multidomian proteins that interact with a wide variety of transcription factors and corepressor components, and we examined whether disruption of the function of a specific domain could lead to epigenetic reprogramming and derepression of specific subsets of genes. To this end, we selected the Sin3A/B-paired amphipathic alpha-helices (PAH2) domain based on its established role in mediating the effects of a relatively small number of transcription factors containing a PAH2-binding motif known as the Sin3 interaction domain (SID). Here, we show that in both human and mouse breast cancer cells, the targeted disruption of Sin3 function by introduction of a SID decoy that interferes with PAH2 binding to SID-containing partner proteins reverted the silencing of genes involved in cell growth and differentiation. In particular, the SID decoy led to epigenetic reprogramming and reexpression of the important breast cancer-associated silenced genes encoding E-cadherin, estrogen receptor alpha, and retinoic acid receptor beta and impaired tumor growth in vivo. Interestingly, the SID decoy was effective in the triple-negative M.D. Anderson-Metastatic Breast-231 (MDA-MB-231) breast cancer cell line, restoring sensitivity to 17beta-estradiol, tamoxifen, and retinoids. Therefore, the development of small molecules that can block interactions between PAH2 and SID-containing proteins offers a targeted epigenetic approach for treating this type of breast cancer that may also have wider therapeutic implications.

Indexed as

Amino Acid SequenceAnimalsBase SequenceBreast NeoplasmsCell DifferentiationCell Line, TumorChromatin Assembly and DisassemblyDNA PrimersDrug Resistance, NeoplasmEpigenesis, GeneticEstrogen Receptor alphaFemaleGene TargetingGenetic TherapyHumansMammary Neoplasms, ExperimentalDNA PrimersEstrogen Receptor alphaReceptors, Retinoic AcidRepressor Proteinsretinoic acid receptor betaSIN3A transcription factorSIN3B protein, humanSin3b protein, mouseSin3 Histone Deacetylase and Corepressor Complex

Identifiers

PMID20547842
PMCPMC2900697
OpenAlexW2013758314

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.